Onconetix, Inc. Annual Report - Your Investor's Guide for the Fiscal Year Ended December 31, 2025

Considering an investment in Onconetix, Inc.? This guide cuts through the jargon to help you understand their past year's performance and future prospects, empowering you to make an informed decision.

Below are the key insights from their annual report for the fiscal year ended December 31, 2025:

1. Business Overview

Onconetix, a biotechnology company, made a significant strategic shift this past year. It now primarily focuses on developing and commercializing diagnostic solutions for men's health, particularly prostate cancer.

Their main product is Proclarix, an advanced blood-based diagnostic test for prostate cancer. Onconetix acquired Proclarix by purchasing Proteomedix in December 2023. Proclarix is already approved for sale in the European Union, and Onconetix plans to introduce it to the U.S. market as a lab-developed test through a strategic partnership with LabCorp.

This focus on Proclarix represents a major change. Previously, Onconetix acquired and marketed ENTADFI, a pill for benign prostatic hyperplasia (BPH), in April 2023. However, by the end of 2025, the company decided to completely abandon ENTADFI due to high commercialization costs, significant cash drain, and insufficient resources. Onconetix laid off employees associated with ENTADFI and fully wrote off the product's assets by June 2024, consolidating its efforts entirely on Proclarix.

Looking ahead, the company is pursuing a significant "Share Exchange Agreement" with Realbotix, an AI-powered digital health solutions company. If completed, this transaction would mark another major strategic pivot, potentially diversifying Onconetix into the broader health technology sector.

2. Financial Performance

Onconetix's financial health remains a significant concern. For the fiscal year ended December 31, 2025, the company reported minimal revenue of just $150,000, primarily from early Proclarix sales in the EU. This led to a substantial net loss of $28.5 million for the year, reflecting high research and development, and commercialization expenses.

The company has a history of significant losses and minimal revenue since its inception. It explicitly states it expects to continue incurring losses for the foreseeable future, with no guarantee of ever achieving profitability. This dire financial situation has led management to express "substantial doubt" about Onconetix's ability to continue operating as a "going concern" without securing significant additional funding.

3. Management's Discussion and Analysis (MD&A) Highlights

Management's discussion highlights the critical strategic and financial decisions made during the fiscal year. The company's 2025 financial results, characterized by minimal revenue and a substantial net loss, were primarily driven by costs associated with the strategic pivot and ongoing operational expenses.

The company abandoned ENTADFI because of its unsustainable commercialization costs and the significant drain on its limited cash resources. This move, which included employee layoffs and a full asset write-off, aimed to streamline operations and focus all available resources on the more promising Proclarix diagnostic test. Management views the December 2023 acquisition of Proteomedix and the subsequent focus on Proclarix—including securing EU approval and the LabCorp partnership—as critical steps toward establishing a viable business model.

The company's persistent financial instability and the "going concern" warning underscore the urgent need for additional capital. Management acknowledges that without significant new funding, the company's ability to execute its commercialization plans for Proclarix and pursue the Realbotix transaction will be severely hampered. The 1-for-85 reverse stock split executed in June 2025 primarily aimed to increase the per-share trading price to maintain compliance with Nasdaq listing requirements, reflecting underlying stock price weakness.

Furthermore, the proposed Share Exchange Agreement with Realbotix represents a significant strategic undertaking. Management views this as an opportunity to diversify into the growing digital health sector but also recognizes the complexities and risks associated with integrating two distinct businesses. The company also identified a material weakness in its internal control over financial reporting, specifically related to insufficient personnel with appropriate accounting expertise and a lack of proper segregation of duties. Management is working to remediate this.

4. Financial Health

Onconetix is in a precarious financial position. As of December 31, 2025, the company reported only $1.2 million in cash and cash equivalents, while carrying $15 million in long-term debt. This limited cash reserve, coupled with ongoing losses, means the company urgently needs to raise substantial additional capital to fund its operations, commercialization efforts for Proclarix, and the potential Realbotix transaction.

The "substantial doubt" about their ability to continue as a "going concern" is a critical warning. Without significant new funding, Onconetix may be forced to scale back or even cease operations, including the commercialization of Proclarix. Any capital raised through issuing new shares would likely dilute the ownership percentage of existing shareholders.

As of March 11, 2026, Onconetix had approximately 3.58 million shares of common stock outstanding, with a total market value of common stock held by non-affiliates estimated at only $3.6 million as of June 30, 2025.

5. Risk Factors

Investing in Onconetix carries significant risks:

• Realbotix Transaction Risks: The proposed acquisition of Realbotix, an AI-powered digital health company, is a major undertaking. The deal might not close, or if it does, it could introduce unforeseen liabilities, divert management's focus, and further dilute existing shareholders. Integrating two distinct businesses (diagnostics and digital health) presents significant operational challenges.
• Severe Financial Instability: The company's history of minimal revenue and substantial losses, coupled with limited cash and significant debt, poses an existential threat. The "going concern" warning is a serious indicator of potential insolvency.
• Reliance on a Single Product (Proclarix): With the abandonment of ENTADFI, Onconetix's immediate future hinges almost entirely on the successful commercialization and market acceptance of Proclarix. Any setbacks in regulatory approval (for new indications), market adoption, or competition could be catastrophic.
• Intense Competition: Proclarix faces competition from established diagnostic companies and larger pharmaceutical firms with superior financial, marketing, and R&D resources.
• Market Acceptance and Reimbursement: There's no guarantee that Proclarix will achieve widespread adoption by physicians and patients, particularly in the U.S. market. Securing favorable reimbursement from insurance providers is also a critical and uncertain hurdle.
• Supply Chain and Distribution Challenges: Disruptions in the supply chain, increased manufacturing costs, or difficulties in establishing efficient distribution channels could severely impact Proclarix's profitability and availability.
• Intellectual Property (IP) Protection: Protecting Proclarix's patents and other intellectual property, and potentially Realbotix's technology, is crucial but expensive and challenging. Failure to do so could allow competitors to replicate their offerings.
• Stock Volatility and Delisting Risk: Onconetix's stock price has been highly volatile. There's no guarantee the company can maintain its listing on the Nasdaq exchange, which could further reduce liquidity and investor interest.
• Internal Control Weaknesses: The company identified a material weakness in its internal control over financial reporting, specifically related to insufficient personnel with appropriate accounting expertise and a lack of proper segregation of duties. This raises concerns about the accuracy and reliability of its financial reporting.
• Dilution from Future Capital Raises: Given its urgent need for cash, Onconetix will likely issue more shares, which will dilute the ownership percentage and value of existing shareholders' investments.
• Cybersecurity Risks (Realbotix): If the Realbotix transaction closes, Onconetix will inherit cybersecurity risks associated with handling sensitive patient data and operating digital health platforms.

6. Competitive Position

Onconetix operates in a highly competitive environment. Proclarix competes with other established and emerging prostate cancer diagnostic tests. Many of these competitors are significantly larger, possess greater financial resources, have established sales and marketing infrastructures, and benefit from broader product portfolios. This places Onconetix at a considerable disadvantage, requiring it to effectively differentiate Proclarix and execute flawlessly to gain market share. If completed, the planned Realbotix transaction would also place Onconetix in the highly competitive and rapidly evolving digital health technology sector.

7. Future Outlook

Onconetix's immediate future hinges on three primary objectives:

• Successful Commercialization of Proclarix: Their top priority is to drive sales and market penetration for Proclarix, particularly by leveraging the LabCorp partnership for the U.S. market and expanding in the EU.
• Completion of the Realbotix Transaction: Finalizing this share exchange agreement is crucial for their planned strategic diversification into digital health.
• Securing Substantial Capital: Underlying both these goals is the critical need to raise significant additional funding to sustain operations and support commercialization and integration efforts.

While these moves aim for long-term growth and eventual profitability, the company has explicitly cautioned that it may never reach a profitable state. The planned Realbotix transaction will expose Onconetix to the rapidly evolving and often unpredictable technology industry, including intense competition, rapid technological obsolescence, and the need for continuous innovation. The diagnostic market also faces complex and evolving regulatory requirements (e.g., FDA approval processes, CLIA regulations for lab-developed tests). Changes in these regulations or in reimbursement policies by government and private payers could significantly impact Proclarix's market access and profitability.

Onconetix qualifies as an "Emerging Growth Company" and a "Smaller Reporting Company," which allows for reduced reporting requirements and exemptions from certain regulatory provisions. While this can lower compliance costs for the company, it also means investors may receive less detailed financial and operational information compared to larger, fully reporting public companies, potentially impacting transparency.